Parnax Lab

{
  "main_header": {
    "sid": 286243,
    "name": "Parnax Lab",
    "stock_name": "Parnax Lab",
    "full_name": "Parnax Lab Ltd",
    "name_url": "stocks-analysis/parnax-lab",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "126.60",
    "chg": 0.1,
    "chgp": "0.08%",
    "dir": 1,
    "prev_price": "126.50",
    "mcapval": "145.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 506128,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE383L01019",
    "curr_date": "Jun 11, 02:44 PM",
    "curr_time": "14:50 PM",
    "last_traded_at": "Jun 11, 02:44 PM IST",
    "bse_nse_vol": "5.92 k",
    "exc_status": "Active",
    "traded_date": "Jun 11, 2026",
    "traded_date_str": "2026 06 11",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/parnax-lab-286243-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Parnax Lab Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/parnax-lab-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-market-volatility-4025084",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ParnaxLabLtd_valuationdot_4025084.png",
        "date": "2026-06-01 08:01:28",
        "description": "Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from fair to attractive territory. Despite a recent downgrade in its Mojo Grade to Sell, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for value-oriented investors seeking exposure in this sector."
      },
      {
        "title": "Parnax Lab Ltd Reports Flat Quarterly Financial Performance Amid Margin Pressures",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/parnax-lab-ltd-reports-flat-quarterly-financial-performance-amid-margin-pressures-4024910",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ParnaxLabLtd_fintrenddot_4024910.png",
        "date": "2026-06-01 08:00:17",
        "description": "Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, signalling a notable shift from its previously positive growth trajectory. Despite achieving record quarterly net sales, the company’s profitability and margin metrics have deteriorated, prompting a downgrade in its Mojo Grade from Hold to Sell as of 25 March 2026."
      },
      {
        "title": "Parnax Lab Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/parnax-lab-ltd-is-rated-sell-4024341",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ParnaxLabLtd_mojoScore_4024341.png",
        "date": "2026-05-31 10:10:18",
        "description": "Parnax Lab Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 May 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Are Parnax Lab Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-parnax-lab-ltd-latest-results-good-or-bad-4023707",
        "imagepath": "",
        "date": "2026-05-30 19:38:36",
        "description": "Parnax Lab Ltd's latest financial results for Q4 FY26 present a complex picture characterized by strong revenue growth but significant challenges in profitability. The company reported net sales of ₹69.63 crores, marking a sequential growth of 10.63% and a year-on-year increase of 41.99%. This performance represents the highest quarterly revenue on record for Parnax Lab, indicating a robust top-line trajectory.\n\nHowever, this revenue growth did not translate into net profit growth, which fell to ₹2.18 crores, reflecting a decline of 19.56% quarter-on-quarter and 25.34% year-on-year. The operating margin decreased sharply to 7.02%, the lowest level in eight quarters, highlighting substantial cost pressures that have impacted the company's profitability. The profit after tax (PAT) margin also contracted to 3.13%, down from 4.32% in the previous quarter, indicating a weakening in overall financial health.\n\nAdd..."
      },
      {
        "title": "Parnax Lab Q4 FY26: Margin Compression Clouds Strong Revenue Growth",
        "link": "https://www.marketsmojo.com/news/result-analysis/parnax-lab-q4-fy26-margin-compression-clouds-strong-revenue-growth-4022952",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ParnaxLab_quaterlyResult_4022952.png",
        "date": "2026-05-29 22:32:25",
        "description": "Parnax Lab Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹170.00 crores, reported net profit of ₹2.18 crores for Q4 FY26 (Mar'26 quarter), marking a concerning decline of 19.56% quarter-on-quarter and 25.34% year-on-year. Despite robust revenue growth, the company's profitability came under severe pressure due to margin compression and elevated other income dependency, raising questions about the sustainability of its operational performance."
      },
      {
        "title": "Parnax Lab Ltd Valuation Shifts to Fair Amid Strong Long-Term Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/parnax-lab-ltd-valuation-shifts-to-fair-amid-strong-long-term-returns-4012360",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ParnaxLabLtd_valuationdot_4012360.png",
        "date": "2026-05-26 08:00:30",
        "description": "Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a robust long-term return profile, recent changes in key valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a recalibration of investor sentiment amid broader market dynamics."
      },
      {
        "title": "When is the next results date for Parnax Lab Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-parnax-lab-ltd-4003759",
        "imagepath": "",
        "date": "2026-05-21 23:17:38",
        "description": "The next results date for Parnax Lab Ltd is scheduled for 28 May 2026...."
      },
      {
        "title": "Parnax Lab Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/parnax-lab-ltd-is-rated-hold-4000883",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ParnaxLabLtd_mojoScore_4000883.png",
        "date": "2026-05-20 10:10:03",
        "description": "Parnax Lab Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Parnax Lab Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/parnax-lab-ltd-valuation-shifts-signal-renewed-price-attractiveness-4000015",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ParnaxLabLtd_valuationdot_4000015.png",
        "date": "2026-05-20 08:00:32",
        "description": "Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from a previously fair to an attractive valuation grade. This change, coupled with a recent upgrade in its Mojo Grade from Strong Sell to Hold, signals a potential reappraisal of the stock’s price attractiveness amid improving fundamentals and relative sector comparisons."
      }
    ],
    "total": 290,
    "sid": "286243",
    "stock_news_url": "https://www.marketsmojo.com/news/parnax-lab-286243"
  },
  "announcements": [
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "30-May-2026",
      "details": "Please find enclosed herewith the Annual Secretarial Compliance Report under reg. 24(A) for the Year ended March 2026.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Board Meeting Outcome For Consideration And Approval Of Standalone & Consolidated Audited Financial Results Of The Company For The Quarter And Year Ended 31St March 2026 Along With AuditorS Report Thereon.",
      "datetime": "28-May-2026",
      "details": "Board Meeting Outcome for Consideration and Approval of Standalone & Consolidated Audited Financial Results of the Company for the quarter and year ended 31st March 2026 along with Auditors Report thereon and Re-appointment of Mr. Yogesh Varia as an Independent Director.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "28-May-2026",
      "details": "Please find enclosed herewith the Intimation regarding the Re-appointment of Mr. Yogesh K. Varia as an Independent Director of the Company for a second term of 5 consecutive years w.e.f. 28th May 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Parnax Lab Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Market Volatility

2026-06-01 08:01:28

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from fair to attractive territory. Despite a recent downgrade in its Mojo Grade to Sell, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for value-oriented investors seeking exposure in this sector.

Read full news article

Parnax Lab Ltd Reports Flat Quarterly Financial Performance Amid Margin Pressures

2026-06-01 08:00:17

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, signalling a notable shift from its previously positive growth trajectory. Despite achieving record quarterly net sales, the company’s profitability and margin metrics have deteriorated, prompting a downgrade in its Mojo Grade from Hold to Sell as of 25 March 2026.

Read full news article

Parnax Lab Ltd is Rated Sell

2026-05-31 10:10:18

Parnax Lab Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Are Parnax Lab Ltd latest results good or bad?

2026-05-30 19:38:36

Parnax Lab Ltd's latest financial results for Q4 FY26 present a complex picture characterized by strong revenue growth but significant challenges in profitability. The company reported net sales of ₹69.63 crores, marking a sequential growth of 10.63% and a year-on-year increase of 41.99%. This performance represents the highest quarterly revenue on record for Parnax Lab, indicating a robust top-line trajectory. However, this revenue growth did not translate into net profit growth, which fell to ₹2.18 crores, reflecting a decline of 19.56% quarter-on-quarter and 25.34% year-on-year. The operating margin decreased sharply to 7.02%, the lowest level in eight quarters, highlighting substantial cost pressures that have impacted the company's profitability. The profit after tax (PAT) margin also contracted to 3.13%, down from 4.32% in the previous quarter, indicating a weakening in overall financial health. Add...

Read full news article

Parnax Lab Q4 FY26: Margin Compression Clouds Strong Revenue Growth

2026-05-29 22:32:25

Parnax Lab Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹170.00 crores, reported net profit of ₹2.18 crores for Q4 FY26 (Mar'26 quarter), marking a concerning decline of 19.56% quarter-on-quarter and 25.34% year-on-year. Despite robust revenue growth, the company's profitability came under severe pressure due to margin compression and elevated other income dependency, raising questions about the sustainability of its operational performance.

Read full news article

Parnax Lab Ltd Valuation Shifts to Fair Amid Strong Long-Term Returns

2026-05-26 08:00:30

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a robust long-term return profile, recent changes in key valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a recalibration of investor sentiment amid broader market dynamics.

Read full news article

When is the next results date for Parnax Lab Ltd?

2026-05-21 23:17:38

The next results date for Parnax Lab Ltd is scheduled for 28 May 2026....

Read full news article

Parnax Lab Ltd is Rated Hold

2026-05-20 10:10:03

Parnax Lab Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Parnax Lab Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-05-20 08:00:32

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from a previously fair to an attractive valuation grade. This change, coupled with a recent upgrade in its Mojo Grade from Strong Sell to Hold, signals a potential reappraisal of the stock’s price attractiveness amid improving fundamentals and relative sector comparisons.

Read full news article

View All News